A Randomized, Two-Treatments, Two-Periods, Crossover, Open label, Laboratory-Blind, Single Dose Bioequivalence Study between Vildagliptin/Metformin 50 mg/1000 mg Film Coated Tablets (Sensityn^®) and Galvusmet^® 50 mg/1000 mg Film Coated Tablets in healthy adults under fed conditions

[1] WHO. Global Report on Diabetes. 2016;1–88. WHO Global Report on Diabetes 2016 1 88 Search in Google Scholar

[2] Saudi National Diabetes Center (SNDC), SAUDI HEALTH COUNCIL, 1st edition; Aug 2021. Saudi National Diabetes Center (SNDC) SAUDI HEALTH COUNCIL 1st edition Aug 2021 Search in Google Scholar

[3] Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, Khan NB, Al-Khadra A, Al-Marzouki K, Nouh MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobeireek A. Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004;25:1603–1610. Al-NozhaMM Al-MaatouqMA Al-MazrouYY Al-HarthiSS ArafahMR KhalilMZ KhanNB Al-KhadraA Al-MarzoukiK NouhMS AbdullahM AttasO Al-ShahidMS Al-MobeireekA Diabetes mellitus in Saudi Arabia Saudi Med J. 2004 25 1603 1610 Search in Google Scholar

[4] Eligar VS, Bain SC. A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment. Drug Des. Devel. Ther. 2013;7:893–903. EligarVS BainSC A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment Drug Des. Devel. Ther. 2013 7 893 903 Search in Google Scholar

[5] NICE. Managing blood glucose in adults with type 2 diabetes. 2016;1–24. NICE Managing blood glucose in adults with type 2 diabetes 2016 1 24 Search in Google Scholar

[6] American Diabetes Association. Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers. Clin Diabetes. 2022;40:10–38. American Diabetes Association Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers Clin Diabetes. 2022 40 10 38 Search in Google Scholar

[7] Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane.Database.Syst.Rev. 2005; CD002966. SaenzA Fernandez-EstebanI MataixA AusejoM RoqueM MoherD Metformin monotherapy for type 2 diabetes mellitus Cochrane.Database.Syst.Rev. 2005 CD002966 Search in Google Scholar

[8] Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab.Vasc.Dis.Res. 2008;5: 157–167. ScarpelloJH HowlettHC Metformin therapy and clinical uses Diab.Vasc.Dis.Res. 2008 5 157 167 Search in Google Scholar

[9] Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. Front Endocrinol.(Lausanne) 2020;11:191. LvZ GuoY Metformin and Its Benefits for Various Diseases Front Endocrinol.(Lausanne) 2020 11 191 Search in Google Scholar

[10] Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13:7–18. DeaconCF Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review Diabetes Obes Metab. 2011 13 7 18 Search in Google Scholar

[11] Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care. 2007;30:1335–1343. DruckerDJ Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action Diabetes Care 2007 30 1335 1343 Search in Google Scholar

[12] Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10:82–90. BolliG DottaF RochotteE CohenSE Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study Diabetes Obes Metab 2008 10 82 90 Search in Google Scholar

[13] Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahren B, Byiers S, Shao Q, Dejager S. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11:157–166. FerranniniE FonsecaV ZinmanB MatthewsD AhrenB ByiersS ShaoQ DejagerS Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy Diabetes Obes Metab 2009 11 157 166 Search in Google Scholar

[14] Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010:27;318–326. FilozofC GautierJF A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study Diabet Med. 2010 27 318 326 Search in Google Scholar

[15] Jeon HJ, Oh, TK. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J. 2011;35:529–535. JeonHJ OhTK Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients Diabetes Metab J. 2011 35 529 535 Search in Google Scholar

[16] Mathieu C, Kozlovski P, Paldanius PM, Foley JE, Modgill V, Evans M, Serban C. Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. Eur Endocrinol. 2017;13: 68–72. MathieuC KozlovskiP PaldaniusPM FoleyJE ModgillV EvansM SerbanC Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance Eur Endocrinol 2017 13 68 72 Search in Google Scholar

[17] American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45:S125–S143. American Diabetes Association Professional Practice Committee DrazninB ArodaVR BakrisG BensonG BrownFM FreemanR GreenJ HuangE IsaacsD KahanS LeonJ LyonsSK PetersAL PrahaladP ReuschJEB Young-HymanD 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022 Diabetes Care. 2022 45 S125 S143 Search in Google Scholar

[18] Del Prato S, Foley JE, Kothny W, Kozlovski P, Stumvoll M, Paldánius PM, Matthews DR. Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. Diabet Med. 2014;31:1178–1184. Del PratoS FoleyJE KothnyW KozlovskiP StumvollM PaldániusPM MatthewsDR Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial Diabet Med. 2014 31 1178 1184 Search in Google Scholar

[19] Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394:1519–1529. MatthewsDR PaldániusPM ProotP ChiangY StumvollM Del PratoS VERIFY study group Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial Lancet 2019 394 1519 1529 Search in Google Scholar

[20] The GCC Guidelines for Bioequivalence. 2011;1–47. The GCC Guidelines for Bioequivalence 2011 1 47 Search in Google Scholar

[21] EMA. Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr**). 2010;1–27. EMA Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr**) 2010 1 27 Search in Google Scholar